Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer

@inproceedings{Laar2011GenomicSF,
  title={Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer},
  author={Ryan K van Laar},
  booktitle={BMC Medical Genomics},
  year={2011}
}
Improved methods are needed for predicting prognosis and the benefit of delivering adjuvant chemotherapy (ACT) in patients with non-small-cell lung cancer (NSCLC). A novel prognostic algorithm was identified using genomic profiles from 332 stage I-III adenocarcinomas and independently validated on a separate series of 264 patients with stage I-II tumors, compiled from five previous studies. The prognostic algorithm was used to interrogate genomic data from a series of patients treated with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS